BRKR
BEARISH
$50.33
Live
Bruker Corporation · NASDAQ
Target $54.07
(+7.4%)
$28.53
52W Range
$59.4
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$7.65B
P/E
N/A
ROE
-1.1%
Profit margin
-0.6%
Debt/Equity
0.82
Dividend yield
0.38%
AI Analysis
AI-powered fundamental assessment
Confidence
75%
The Advanced Deterministic Scorecard reveals a weak fundamental profile with a Piotroski F-Score of just 2/9, indicating poor financial health. Despite a reasonable Price/Book of 3.13 and a Forward P/E of 23.49 that is below sector average, the company is unprofitable with a negative profit margin (-0.61%) and ROE (-1.09%). Revenue is flat, earnings volatility is high, and insider selling of $2.76M over the past six months signals management skepticism. While the technical rebound from 6-month lows has lifted price performance (+20.3% over 6M), the long-term trend remains weak with a 3Y return of -28.5%, and analyst target of $54.07 appears optimistic given deteriorating fundamentals.
Key Strengths
Gross margin remains strong at 48.83%, indicating pricing power or efficient cost control at production level
Operating margin of 12.96% is healthy relative to sector average of -18.86%
Current ratio of 1.85 suggests adequate short-term liquidity
Analyst recommendation consensus is 'buy' with a target price above current level
Recent quarterly EPS showed explosive Q/Q growth of +800.0%, indicating potential turnaround
Key Risks
Piotroski F-Score of 2/9 signals severe financial distress and weak earnings quality
Negative net profit margin (-0.61%) and ROE (-1.09%) indicate core profitability issues
Revenue growth is negative YoY (-0.50%), reflecting stagnation in top line
Insiders have sold $2.76M in shares over last 6 months with no buys, signaling lack of confidence
Long-term price performance is deeply negative: -28.5% over 3Y and -14.9% over 5Y
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
40
Moderate
45
50
30
20
55
AI Verdict
High risk, low quality, overvalued relative to fundamentals
Key drivers: Low Piotroski F-Score, Negative profitability metrics, Insider selling, Weak long-term returns, Earnings volatility
Confidence
78%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 23.49 is below sector average of 215
- Price/Sales of 2.22 is reasonable for medical devices
Watchpoints
- No Graham Number or intrinsic value available
- P/E ratio not calculable due to negative earnings
Future
50/100
Ref Growth rates
Positives
- Q/Q EPS growth of +800.0% suggests possible recovery
- Analyst target implies 7.4% upside
Watchpoints
- YoY EPS growth is -25.0%
- Revenue growth is negative (-0.50%)
- PEG ratio unavailable due to unreliable earnings
Past
30/100
Ref Historical trends
Positives
- Historically beat earnings estimates in many quarters prior to 2025
Watchpoints
- Only 1 of last 4 quarters beat estimates
- Average earnings surprise over last 4 quarters: -14.58%
- 5Y price return: -14.9%, 3Y: -28.5%
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.85 indicates short-term solvency
- Debt/Equity of 0.82 is below sector average of 2.46
Watchpoints
- Piotroski F-Score of 2/9 indicates severe financial weakness
- ROE is negative (-1.09%)
- Quick ratio of 0.84 suggests potential liquidity strain if inventory cannot be liquidated
Dividend
55/100
Ref Yield, Payout
Positives
- Payout ratio of 38.46% is sustainable
- Dividend yield is positive at 0.38%
Watchpoints
- Dividend strength score is only 40/100
- Low yield offers minimal income appeal
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$50.33
Analyst Target
$54.07
Upside/Downside
+7.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BRKR and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BRKR
Bruker Corporation
Primary
|
-14.9% | -28.5% | -13.1% | +20.3% | +4.6% | +4.0% |
|
KRYS
Krystal Biotech, Inc.
Peer
|
+264.6% | +209.6% | +61.2% | +42.7% | +1.6% | -0.8% |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Peer
|
-23.4% | +107.3% | +265.3% | +85.2% | -10.6% | -8.0% |
|
IBRX
ImmunityBio, Inc.
Peer
|
-54.8% | +372.7% | +195.9% | +208.5% | -12.0% | -0.3% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-40.4% | -45.2% | -50.0% | -23.3% | +11.7% | +2.4% |
BRK
Bruker Corporation
Primary
5Y
-14.9%
3Y
-28.5%
1Y
-13.1%
6M
+20.3%
1M
+4.6%
1W
+4.0%
KRY
Krystal Biotech, Inc.
Peer
5Y
+264.6%
3Y
+209.6%
1Y
+61.2%
6M
+42.7%
1M
+1.6%
1W
-0.8%
ARW
Arrowhead Pharmaceuticals, Inc.
Peer
5Y
-23.4%
3Y
+107.3%
1Y
+265.3%
6M
+85.2%
1M
-10.6%
1W
-8.0%
IBR
ImmunityBio, Inc.
Peer
5Y
-54.8%
3Y
+372.7%
1Y
+195.9%
6M
+208.5%
1M
-12.0%
1W
-0.3%
MOH
Molina Healthcare, Inc.
Peer
5Y
-40.4%
3Y
-45.2%
1Y
-50.0%
6M
-23.3%
1M
+11.7%
1W
+2.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
23.49
PEG Ratio
N/A
P/B Ratio
3.13
P/S Ratio
2.22
EV/Revenue
2.75
EV/EBITDA
16.18
Market Cap
$7.65B
Profitability
Profit margins and return metrics
Profit Margin
-0.61%
Operating Margin
12.96%
Gross Margin
48.83%
ROE
-1.09%
ROA
3.69%
Growth
Revenue and earnings growth rates
Revenue Growth
-0.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.82
Moderate
Current Ratio
1.85
Good
Quick Ratio
0.84
Poor
Cash/Share
$1.94
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-12
$N/A
2025-11-03
$0.45
+38.8% surprise
2025-08-04
$0.05
-37.5% surprise
2025-05-07
$0.11
-45.0% surprise
Healthcare Sector Comparison
Comparing BRKR against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-1.09%
This Stock
vs
-88.14%
Sector Avg
-98.8%
(Below Avg)
Profit Margin
-0.61%
This Stock
vs
-16.28%
Sector Avg
-96.3%
(Weaker)
Debt to Equity
0.82
This Stock
vs
2.66
Sector Avg
-69.1%
(Less Debt)
Revenue Growth
-0.5%
This Stock
vs
124.04%
Sector Avg
-100.4%
(Slower)
Current Ratio
1.85
This Stock
vs
4.47
Sector Avg
-58.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BRKR
Bruker Corporation
|
BEARISH | $7.65B | - | -1.1% | -0.6% | $50.33 | |
|
KRYS
Krystal Biotech, Inc.
|
NEUTRAL | $7.62B | 37.87 | 18.9% | 52.6% | $259.0 | Compare |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
BULLISH | $7.71B | 34.41 | 75.5% | 18.5% | $55.05 | Compare |
|
IBRX
ImmunityBio, Inc.
|
NEUTRAL | $7.52B | - | -% | -% | $7.28 | Compare |
|
MOH
Molina Healthcare, Inc.
|
BEARISH | $7.87B | 16.83 | 11.0% | 1.1% | $151.0 | Compare |
BRKR
Bruker Corporation
BEARISH
Mkt Cap
$7.6B
P/E
-
ROE
-1.1%
Price
$50.33
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-15 | MUNCH MARK ROBERT | Officer | Option Exercise | 2,000 | $44,380 |
| 2026-01-15 | MUNCH MARK ROBERT | Officer | Sale | 2,000 | $98,400 |
| 2026-01-12 | MUNCH MARK ROBERT | Officer | Option Exercise | 7,000 | $155,330 |
| 2026-01-12 | MUNCH MARK ROBERT | Officer | Sale | 7,000 | $385,000 |
| 2026-01-05 | MUNCH MARK ROBERT | Officer | Option Exercise | 33,843 | $750,976 |
| 2026-01-05 | MUNCH MARK ROBERT | Officer | Sale | 33,843 | $1,680,647 |
| 2025-12-01 | PACKER RICHARD A | Director | Option Exercise | 10,000 | $240,000 |
| 2025-12-01 | PACKER RICHARD A | Director | Sale | 5,028 | $243,230 |
| 2025-11-06 | ORNELL JOHN A | Director | Option Exercise | 10,000 | $240,000 |
| 2025-11-06 | ORNELL JOHN A | Director | Sale | 6,233 | $243,087 |
| 2025-09-12 | FRIEND CYNTHIA M | Director | Option Exercise | 4,300 | $112,531 |
| 2025-09-12 | FRIEND CYNTHIA M | Director | Sale | 3,535 | $113,990 |
| 2025-08-15 | LAUKIEN FRANK H | Chief Executive Officer | Stock Award | 48,431 | - |
| 2025-08-15 | HERMAN GERALD N | Chief Financial Officer | Stock Award | 25,844 | - |
| 2025-08-15 | MUNCH MARK ROBERT | Officer | Stock Award | 23,631 | - |
MUNCH MARK ROBERT
Officer
2026-01-15
2,000 shares
·
$44,380
MUNCH MARK ROBERT
Officer
2026-01-15
2,000 shares
·
$98,400
MUNCH MARK ROBERT
Officer
2026-01-12
7,000 shares
·
$155,330
MUNCH MARK ROBERT
Officer
2026-01-12
7,000 shares
·
$385,000
MUNCH MARK ROBERT
Officer
2026-01-05
33,843 shares
·
$750,976
MUNCH MARK ROBERT
Officer
2026-01-05
33,843 shares
·
$1,680,647
PACKER RICHARD A
Director
2025-12-01
10,000 shares
·
$240,000
PACKER RICHARD A
Director
2025-12-01
5,028 shares
·
$243,230
ORNELL JOHN A
Director
2025-11-06
10,000 shares
·
$240,000
ORNELL JOHN A
Director
2025-11-06
6,233 shares
·
$243,087
FRIEND CYNTHIA M
Director
2025-09-12
4,300 shares
·
$112,531
FRIEND CYNTHIA M
Director
2025-09-12
3,535 shares
·
$113,990
LAUKIEN FRANK H
Chief Executive Officer
2025-08-15
48,431 shares
HERMAN GERALD N
Chief Financial Officer
2025-08-15
25,844 shares
MUNCH MARK ROBERT
Officer
2025-08-15
23,631 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
14 analysts
Citigroup
2026-01-16
Neutral
Neutral
TD Cowen
2026-01-07
Hold
Hold
Guggenheim
2026-01-05
Buy
Buy
Barclays
2025-12-15
Overweight
Overweight
JP Morgan
2025-12-15
Overweight
Overweight
Wells Fargo
2025-12-15
Overweight
Overweight
B of A Securities
2025-12-15
Buy
Buy
Wolfe Research
2025-12-10
Peer Perform
Outperform
Goldman Sachs
2025-12-09
Sell
Rothschild & Co
2025-11-20
Buy
Past News Coverage
Recent headlines mentioning BRKR from our newsroom.
Newest → oldest
No matching news yet.